These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17313464)

  • 21. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients.
    van Burik JA; Lawatsch EJ; DeFor TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2001; 7(12):674-9. PubMed ID: 11787530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
    Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.
    Pagano L; Caira M; Nosari A; Van Lint MT; Candoni A; Offidani M; Aloisi T; Irrera G; Bonini A; Picardi M; Caramatti C; Invernizzi R; Mattei D; Melillo L; de Waure C; Reddiconto G; Fianchi L; Valentini CG; Girmenia C; Leone G; Aversa F
    Clin Infect Dis; 2007 Nov; 45(9):1161-70. PubMed ID: 17918077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
    Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
    Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
    Grigg A; Chapman R; Szer J
    Bone Marrow Transplant; 1998 Mar; 21(6):619-21. PubMed ID: 9543067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
    Resnick IB; Abdul Hai A; Shapira MY; Bitan M; Hershkovitz E; Schwartz A; Ben-Harush M; Or R; Slavin S; Kapelushnik J
    Clin Transplant; 2005 Dec; 19(6):840-7. PubMed ID: 16313334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.
    Panigrahi S; Nagler A; Or R; Wolf DG; Slavin S; Shapira MY
    Bone Marrow Transplant; 2001 Mar; 27(6):659-61. PubMed ID: 11319599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.
    Mikulska M; Raiola AM; Bruno B; Furfaro E; Van Lint MT; Bregante S; Ibatici A; Del Bono V; Bacigalupo A; Viscoli C
    Bone Marrow Transplant; 2009 Sep; 44(6):361-70. PubMed ID: 19308042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
    Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
    Yanagisawa R; Nakazawa Y; Sakashita K; Tanaka M; Shikama N; Kamijo T; Shiohara M; Koike K
    Pediatr Transplant; 2009 Sep; 13(6):737-45. PubMed ID: 19207225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.